
Despite a trial miss, Cognito plans to seek FDA authorization for its light and sound Alzheimer's headset next year. #CTAD26 endpoints.news/ctad26-cognit…
✓The biopharma world is here. Get the industry’s most comprehensive daily news reports at endpts.com/subscribe

Despite a trial miss, Cognito plans to seek FDA authorization for its light and sound Alzheimer's headset next year. #CTAD26 endpoints.news/ctad26-cognit…

Sellas says its cancer vaccine cut the risk of death by 41% in a Phase 3 AML trial, sending shares up 165%. endpoints.news/sellas-claims…

Isomorphic's $5B Series C is the largest private raise in biotech history, though the Google-backed AI biotech has yet to reach the clinic. endpoints.news/analysis-3-th…

Marrow raised $173M for an siRNA drug it hopes can compete with a one-time CRISPR therapy for sickle cell. endpoints.news/marrow-raises…

Roche entered the SERD market with FDA approval of its breast cancer pill Wilserdly in late-stage disease, more than a month early. endpoints.news/roche-enters-…

Lilly struck a cancer deal worth up to $5.9B with Stipple Bio, its second-largest collaboration this year by total deal value. endpoints.news/lilly-strikes…

Q&A: "I don't think we have a science funding problem. We have a translation problem," Parker Institute CEO Karen Knudsen told Endpoints' Ryan Cross. endpoints.news/parker-instit…

Lilly is buying little-known blood cancer biotech Calytrix Bio for up to $1.5B, its 14th acquisition of the year. endpoints.news/lillys-14th-a…

J&J is buying eye disease biotech Ollin Biosciences for up to $3.3B, just over a year after the startup broke cover with assets from China. endpoints.news/jj-to-buy-eye…

Seawolf launched with $100M for a non-viral gene therapy it hopes can tackle obesity, muscle loss and osteoporosis at once. endpoints.news/seawolf-launc…

Sofinnova closed its second crossover fund at €725M to fill the financing gap for late-stage European biotechs. endpoints.news/sofinnova-clo…

The FDA rejected Summit and Akeso's ivonescimab in a narrow lung cancer setting, sending both stocks down more than 20%. endpoints.news/fda-rejects-s…

Milestone is cutting 20% of its staff, with its CMO and CFO exiting, as heart drug Cardamyst brought in $1M in Q3 sales. endpoints.news/milestone-cut…

Moderna says it's "on track and ready" to make thousands of doses of its cancer vaccine as it prepares to file with the FDA by year-end. endpoints.news/moderna-readi…

Even if AI can create more molecules, it doesn't necessarily lead to "proof of concept in a human being," said Karen Akinsanya, head of therapeutics R&D at Schrödinger. But those molecules could help probe human biology, she said at Endpoints' AI Day in New York City. Catch up on her "hot take" here: youtu.be/947MuBm2MSk?si=c-XV…

Windward Bio raised $175M in its Nasdaq IPO, plus $50M from Sanofi, becoming the 30th biotech to go public this year. endpoints.news/windward-bio-…